Bleeding associated with antithrombotic therapy.
D015110:4-Hydroxycoumarins / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D003911:Dextrans / Q000009:adverse effects / Q000627:therapeutic use; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced*; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D012306:Risk; D013299:Streptodornase and Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D013442:Sulfinpyrazone / Q000009:adverse effects / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D013927:Thrombosis / Q000188:drug therapy
D015110:4-Hydroxycoumarins; D003911:Dextrans; D005343:Fibrinolytic Agents; D004176:Dipyridamole; D006493:Heparin; D013299:Streptodornase and Streptokinase; D001241:Aspirin; D013442:Sulfinpyrazone